These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 20371657

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome.
    Möhlig M, Weickert MO, Ghadamgahi E, Arafat AM, Spranger J, Pfeiffer AF, Schöfl C.
    Eur J Endocrinol; 2008 Apr; 158(4):517-23. PubMed ID: 18362299
    [Abstract] [Full Text] [Related]

  • 23. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
    Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, Azizi F.
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z.
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
    Zwirska-Korczala K, Konturek SJ, Sodowski M, Wylezol M, Kuka D, Sowa P, Adamczyk-Sowa M, Kukla M, Berdowska A, Rehfeld JF, Bielanski W, Brzozowski T.
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
    [Abstract] [Full Text] [Related]

  • 31. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall'Alda M, Spiazzi G, Zanolin ME, Bonora E.
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [Abstract] [Full Text] [Related]

  • 32. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
    Li L, Chen X, He Z, Zhao X, Huang L, Yang D.
    J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
    [Abstract] [Full Text] [Related]

  • 33. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M, Sahin Ersoy G, Yayla Abide C, Sanverdi İ, Devranoglu B, Kutlu T, Çevik Ö.
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [Abstract] [Full Text] [Related]

  • 34. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
    Arikan S, Bahceci M, Tuzcu A, Kale E, Gökalp D.
    Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
    [Abstract] [Full Text] [Related]

  • 35. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO, Yarali H, Oguz H, Bayraktar M.
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [Abstract] [Full Text] [Related]

  • 36. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK, Mário FM, Alves BC, Spritzer PM.
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [Abstract] [Full Text] [Related]

  • 37. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
    Patlolla S, Vaikkakara S, Sachan A, Venkatanarasu A, Bachimanchi B, Bitla A, Settipalli S, Pathiputturu S, Sugali RN, Chiri S.
    Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
    [Abstract] [Full Text] [Related]

  • 38. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
    Karadağ C, Yoldemir T, Gogas Yavuz D.
    Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
    [Abstract] [Full Text] [Related]

  • 39. Association between red blood cell distribution width and polycystic ovary syndrome.
    Yilmaz Ö, Mehmet C, Kelekci S, Temur M.
    Endocr Res; 2015 Mar; 40(4):181-7. PubMed ID: 25531764
    [Abstract] [Full Text] [Related]

  • 40. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.
    Coviello AD, Legro RS, Dunaif A.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):492-7. PubMed ID: 16249280
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.